Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
NCT00003399
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy in treating patients who have multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/15/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Register for Updates
Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source
NCT02167958
Completed
The purpose of this study is to determine whether stem cells collected from a donor's blood stream will be as safe and effective as using bone marrow collected from a donor's pelvic bone.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/11/2019
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Leukemia, MDS, Myelofibrosis, Lymphoma
Register for Updates
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
NCT01583686
Terminated
Background: The National Cancer Institute (NCI) Surgery Branch has developed an experimental therapy for treating patients with metastatic cancer that involves taking white blood cells from the patient, growing them in the laboratory in large numbers, genetically modifying these specific cells with a type of virus (retrovirus) to attack only the tumor cells, and then giving the cells back to the patient. This type of therapy is called gene transfer. In this protocol, we are modifying the patien... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/10/2019
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Cervical Cancer, Pancreatic Cancer, Ovarian Cancer, Mesothelioma, Lung Cancer
Register for Updates
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00301821
Completed
RATIONALE: Monoclonal antibodies, such as epratuzumab and rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving monoclonal antib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2019
Locations: Mayo Clinic Scottsdale, Scottsdale, Arizona +161 locations
Conditions: Lymphoma
Register for Updates
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
NCT00392990
Completed
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving rituximab together with combination chemotherapy may kil... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2019
Locations: Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois +7 locations
Conditions: Lymphoma
Register for Updates
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
NCT02215967
Completed
Background: - T cells are white blood cells that fight several cancers. One cancer therapy involves removing a persons' T cells, changing them in a lab, and then returning them to the person. Researchers want to see if this helps people with multiple myeloma. Objective: - To test the safety of giving anti-B-Cell Maturation Antigen T cells to people with multiple myeloma. Eligibility: - Adults ages 18-70 with multiple myeloma that has not responded to standard therapies. Design: * Particip... Read More
Gender:
ALL
Ages:
Between 18 years and 73 years
Trial Updated:
09/20/2019
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland
Conditions: Myeloma, Plasma-Cell, Myeloma-Multiple
Register for Updates
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
NCT02080195
Terminated
The main goal of the study is to determine if bone marrow transplant (BMT) from a less specific pool of donors in combination with high dose cyclophosphamide can induce remission of refractory systemic lupus erythematosus.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/19/2019
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland
Conditions: Lupus Erythematosus, Graft-versus-host Disease
Register for Updates
Phase II Trial for Large ER-Negative Breast Cancers
NCT01869192
Completed
A primary objective of this study is to evaluate the in vivo response of tumor to chemotherapy through gene microarray analysis. Neoadjuvant treatment allows the unique opportunity to observe the in vivo effects of cytotoxic therapy on gene expression in tumor tissue. The investigators plan to evaluate several different questions by comparing gene profiles in different phases of treatment in this study. These are outlined below. Hypotheses 1. Chemotherapy enriches for tumor cell populations th... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/11/2019
Locations: University of Colorado Cancer Center, Aurora, Colorado
Conditions: Malignant Neoplasm of Female Breast
Register for Updates
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
NCT01581970
Completed
This is a feasibility study to assess the effectiveness of cetuximab when administered with low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and neck who have progressed on first line chemotherapy other than a cetuximab containing regimen will be treated with standard of care weekly cetuximab and twice daily low dose oral cyclophosphamide for 12 weeks.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2019
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Register for Updates
Hematopoietic Stem Cell Transplant for Fanconi Anemia
NCT01071239
Completed
The trial proposed is a single arm phase II treatment protocol designed to examine engraftment, toxicity, graft-versus-host disease, and ultimate disease-free survival following a novel cytoreductive regimen including busulfan, cyclophosphamide and fludarabine and anti-thymocyte globulin (ATG- a non-chemotherapy drug whose role is to kill your immune system) for the treatment of patients with Fanconi anemia who have severe aplastic anemia (SAA), or myelodysplastic syndrome (MDS) or acute myeloge... Read More
Gender:
ALL
Ages:
All
Trial Updated:
09/03/2019
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Fanconi Anemia
Register for Updates
SMAC Mimetic LCL161 Alone or With Cyclophosphamide in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT01955434
Completed
This phase II trial studies how well second mitochondrial-derived activator of caspases (SMAC) mimetic LCL161 alone or with cyclophosphamide works in treating patients with multiple myeloma that has returned or does not respond to treatment. Biological therapies, such as SMAC mimetic LCL161, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2019
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Register for Updates
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
NCT03575234
Withdrawn
This phase I trial studies the side effects of nivolumab and IRX-2 and how well they work in treating participants with stage III-IVA oral cavity cancer or human papillomavirus (HPV)-positive oropharyngeal cancer that can be removed by surgery. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. IRX-2 may "turn on" the immune system and stimulate an immune response against tumor cells. Giving nivolumab and IRX-2 followed by surgery may work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2019
Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations
Conditions: Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
Register for Updates